Argos Therapeutics (ARGS) Tops Q3 EPS by 3c

Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.32), $0.03 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $145.76 thousand versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight